EP2146721 - Bibliographic data

METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL

Last update 07/07/2025
Legal status Brevet déchu
Origin Euro-PCT
(73) Holder

OTSUKA PHARMACEUTICAL CO., LTD.

2-9, Kanda-Tsukasamachi Chiyoda-ku
Tokyo 101-8535
Japon
(72) Inventors

LIU, Yongge

c/o Otsuka Maryland Medicinal Laboratories, Inc. 9900 Medical Center Drive
Rockville, Maryland 20850
États-Unis d'Amérique

KAMBAYASHI, Junichi

c/o Otsuka Maryland Medicinal Laboratories, Inc. 9900 Medical Center Drive
Rockville, Maryland 20850
États-Unis d'Amérique
(74) Agent

Mail recipient

CABINET

LAVOIX

2 Place d'Estienne d'Orves
75441
PARIS CEDEX 09
France
(21) Request number EP08755284.0
(22) Request date 12/05/2008
(11) Publication number EP2146721
Publication date 10/07/2013
(54) Title of the invention METHODS FOR USING VASOPRESSIN ANTAGONISTS WITH ANTHRACYCLINE CHEMOTHERAPY AGENTS TO REDUCE CARDIOTOXICITY AND/OR IMPROVE SURVIVAL
(51) International classification A01N 43/00, A61K 31/553, A61K 31/554, A61K 31/55, A61K 45/06
International classification (before reform) None
Claimed priority

(31) Number: 938089 P
(32) Date: 15/05/2007
(33) Country: US

Initial application None
Divisional application None
Expected annuity Annuity: 9 - Amount: 120 € - Due date 31/05/2016
Surtax: 9 - Amount: 24 € - Due date 01/12/2016
Last annuity Annuity: 8 - Payment date 09/04/2015
Publication

BREVETS D'INVENTION DESIGNANT MC DELIVRES PAR l'OEB - bulletin 2013/3, of 30/09/2013

History

Publication de la délivrance du brevet européen - Legal date 10/07/2013

Constitution de mandataire pour un dossier - Legal date 04/09/2013

Entrée en période de grâce du brevet d'invention - Legal date 01/06/2016

Génération de l'avertissement avant déchéance - Legal date 07/06/2016

Déchéance du brevet d'invention après période de grâce - Legal date 31/05/2016